Zoetis Inc. Faces Securities Fraud Class Action Lawsuit
Zoetis Inc. is facing a securities fraud class action lawsuit, alleging the company made misleading statements about its product performance and competitive position between January 2025 and May 2026. Despite the legal challenges, the stock appears significantly undervalued according to GuruFocus, with a GF Value™ of $194.14 against a current price of $74.80, and insiders have been buying shares. Investors are advised to carefully consider these factors.
ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against Zoetis Inc. (NYSE: ZTS) for alleged securities fraud, encouraging investors who purchased shares between January 14, 2025, and May 6, 2026, to come forward by July 27, 2026. The lawsuit claims Zoetis made false statements regarding weakening prescription growth for its Librela medication due to FDA safety warnings, and market share loss for its Trio, Apoquel, and Cytopoint products. Investors are invited to join the case to recover their losses.
ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of a class action lawsuit against Zoetis Inc. (NYSE: ZTS) for securities fraud violations. The lawsuit alleges that Zoetis made false and misleading statements regarding weakening veterinarian prescription growth for its Librela medication due to FDA safety warnings, and market share losses for its Trio, Apoquel, and Cytopoint products. Investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, are encouraged to contact the firm by July 27, 2026, to discuss their rights.
Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Zoetis Inc. (NYSE: ZTS) on behalf of investors who purchased securities between January 14, 2025, and May 6, 2026. The lawsuit alleges that Zoetis made false and misleading statements regarding the growth and market share of its key Companion Animal products, including Librela, Simparica Trio, Apoquel, and Cytopoint. Investors who suffered losses are encouraged to contact the firm to explore lead plaintiff representation by the July 27, 2026 deadline.
ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of a class action lawsuit against Zoetis Inc. (NYSE: ZTS) for alleged securities fraud during the period of January 14, 2025, to May 6, 2026. The lawsuit claims that Zoetis made misleading statements regarding weakening veterinarian prescription growth for its Librela medication, loss of market share for its Trio product, and competition for its Apoquel and Cytopoint dermatology products. Investors who suffered losses are encouraged to contact the firm to discuss their rights.
SG Americas Securities LLC Reduces Stock Position in Elanco Animal Health Incorporated $ELAN
SG Americas Securities LLC significantly reduced its stake in Elanco Animal Health (NYSE: ELAN) by 65.1% in the first quarter, selling 62,227 shares. Despite this reduction, Elanco reported stronger-than-expected quarterly results, with EPS of $0.40 and revenue of $1.37 billion, surpassing analyst estimates. Analyst sentiment remains "Moderate Buy" with an average price target of $28.55, and several firms have recently raised their targets.
ZTS INVESTOR DEADLINE: Zoetis Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against Zoetis Inc. (NYSE: ZTS) on behalf of investors who purchased securities between January 14, 2025, and May 6, 2026. The lawsuit alleges that Zoetis made false and misleading statements regarding the performance of its key companion animal products, including Librela, Simparica Trio, Apoquel, and Cytopoint, resulting in significant stock price declines. Investors with substantial losses have until July 27, 2026, to seek appointment as lead plaintiff in the case.
Should Zoetis’ (ZTS) Shift Into Russell Midcap Indexes After Weaker Guidance Require Investor Action?
Zoetis Inc. was recently moved from Russell Top 200 to Russell Midcap indexes due to weaker guidance stemming from softer U.S. companion-animal demand and increased competition. This shift highlights the impact of recent operational and legal challenges on the company's market classification and assessment. Investors need to consider if Zoetis's broad animal health portfolio and innovation pipeline can overcome current weaknesses, with a focus on stabilizing sales of key pet products.
ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against Zoetis Inc. (NYSE: ZTS) for alleged securities fraud, covering investors who purchased securities between January 14, 2025, and May 6, 2026. The lawsuit claims Zoetis made false and misleading statements regarding the performance of its medications, including Librela, Trio, Apoquel, and Cytopoint, which reportedly suffered from weakening prescription growth and market share loss due to safety warnings and competition. Investors who suffered losses are encouraged to contact the firm to participate in the lawsuit before July 27, 2026.
Michael Burry Just ‘Shorted Micron’ — Why He Says AI-Fueled Rally Has Pushed MU Into Bubble Territory
Michael Burry, known as "The Big Short" investor, has initiated a short position in Micron Technology Inc. (MU), arguing that its recent rally is based on AI hype and FOMO rather than fundamentals. He highlighted the company's historically extreme valuation, poor long-term profitability, and cyclical nature as reasons for anticipated significant downside. Concurrently, Burry increased his long positions in PayPal, Sprouts Farmers Market, Zoetis, Fannie Mae, and Freddie Mac.
Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz announced that shareholders of Zoetis Inc. (ZTS) who suffered losses have an opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges that between January 14, 2025, and May 6, 2026, Zoetis failed to disclose material information regarding weakening prescription growth for Librela, market share loss for Simparica Trio and dermatology products due to new competitors, making their positive statements materially misleading. Investors are encouraged to contact the firm by the lead plaintiff deadline of July 27, 2026.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zoetis Inc. of Class Action Lawsuit and Upcoming Deadlines - ZTS
Pomerantz LLP has filed a class action lawsuit against Zoetis Inc. (NYSE: ZTS) on behalf of investors who suffered losses. The lawsuit alleges securities fraud or unlawful business practices, stemming from Zoetis's May 7, 2026, announcement of lower-than-anticipated Q1 2026 results and reduced full-year profit guidance, which led to a significant drop in its stock price. Investors have until July 27, 2026, to apply to be appointed as Lead Plaintiff.
INVESTOR DEADLINE: Zoetis Inc. (NYSE: ZTS) Investors with
Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against Zoetis Inc. (NYSE: ZTS) for alleged violations of the Securities Exchange Act of 1934. Investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, and suffered substantial losses, have until July 27, 2026, to seek appointment as lead plaintiff. The lawsuit claims Zoetis made false or misleading statements regarding weakening demand for its companion animal products due to safety warnings, market share loss to competitors, and declining sales, leading to significant stock price drops.
Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against Zoetis Inc. (NYSE: ZTS) for alleged violations of federal securities laws. The lawsuit claims that Zoetis made false and misleading statements about its Companion Animal segment products, including Librela, Simparica Trio, Apoquel, and Cytopoint, during the period of January 14, 2025, to May 6, 2026. Investors who purchased Zoetis securities during this period are encouraged to join the case, with a lead plaintiff deadline of July 27, 2026.
IDXX - Idexx Laboratories Inc Volatility & Greeks
This article provides a detailed financial overview of Idexx Laboratories Inc. (IDXX), including its current stock performance, key financial metrics, volatility indicators, and analyst recommendations. It covers various data points from market capitalization to insider transactions and performance across different timeframes, offering a comprehensive snapshot of the company's financial health and stock behavior.
ZOETIS DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL,
Rosen Law Firm is encouraging investors of Zoetis Inc. (NYSE: ZTS) who experienced losses exceeding $100K during the period of January 14, 2025, to May 6, 2026, to secure legal counsel before the lead plaintiff deadline of July 27, 2026. The lawsuit alleges that Zoetis made false and misleading statements regarding its products, including Librela, Simparica Trio, Apoquel, and Cytopoint, resulting in investor damages once the true market conditions became known. Investors can join the class action by contacting the firm.
Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP announces a securities fraud class action lawsuit against Zoetis Inc. (ZTS) for investors who purchased securities between January 14, 2025, and May 6, 2026. The lawsuit alleges that Zoetis made misleading statements about its product adoption, specifically regarding weakening prescription growth for Librela, market share loss for Simparica Trio, and competition for its dermatological products. Investors have until July 27, 2026, to seek lead plaintiff status.
ZOETIS INC. INVESTORS WITH LOSSES HAVE UNTIL JULY 27, 2026
Bernstein Liebhard LLP reminds investors of Zoetis Inc. (NYSE: ZTS) that they have until July 27, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that Zoetis made false and misleading statements between January 14, 2025, and May 6, 2026, causing investors to suffer losses. Investors who owned ZTS shares during this period and lost money are encouraged to contact Bernstein Liebhard LLP.
Zoetis Deadline: ZTS Investors with Losses in Excess of $100K Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit
The Rosen Law Firm reminds Zoetis Inc. (NYSE: ZTS) investors who purchased securities between January 14, 2025, and May 6, 2026, of the July 27, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Zoetis misrepresented key product performance, including weakening sales of Librela due to FDA safety warnings, market share loss for Simparica Trio, and substantial market share loss for its dermatology products. Investors with losses exceeding $100,000 have the opportunity to lead the class action to seek compensation.
Zoetis Deadline: ZTS Investors with Losses in Excess of $100K Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors of Zoetis Inc. (NYSE: ZTS) who experienced losses exceeding $100,000 to consider acting as lead plaintiff in a securities fraud lawsuit. The lawsuit alleges that Zoetis made false and misleading statements about the performance of its key animal health products, including Librela, Simparica Trio, Apoquel, and Cytopoint, during the period of January 14, 2025, to May 6, 2026. Investors have until July 27, 2026, to move for lead plaintiff status.
Class action lawsuit filed against Zoetis after stock drops 21.5% on weak Q1 results and lowered profit guidance
Pomerantz LLP has filed a class action lawsuit against Zoetis Inc. (ZTS) following its disappointing first quarter of 2026 results, which showed flat net income and lowered full-year profit guidance. The company cited a challenging market, leading to a 21.5% drop in stock price. Investors who suffered losses are encouraged to join the lawsuit by July 27, 2026, to hold Zoetis accountable.
Analyst recommendations: Comcast, Fortinet, Delta Air Lines, SanDisk, Zoetis…
This article provides a daily summary of analyst recommendations for North American companies, focusing on those experiencing changes in opinion, price target, or new coverage. It details upgrades, downgrades, and maintained ratings for various companies including Comcast, Fortinet, Delta Air Lines, SanDisk, and Zoetis, along with their respective target price adjustments. The information is intended to offer insight into stock movements and market sentiment.
Bragar Eagel & Squire, P.C. Reminds Zoetis, Inc. Investors that a Class Action Lawsuit Has Been Filed Against Zoetis and Encourages Investors to Contact the Firm Before the July 27th Deadline
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Zoetis, Inc. (NYSE:ZTS) on behalf of investors who purchased securities between January 14, 2025, and May 6, 2026. The lawsuit alleges that Zoetis made misleading statements by failing to disclose issues with weakening growth for Librela, market share loss for Simparica Trio, and challenges to dermatology products Apoquel and Cytopoint. Investors have until July 27, 2026, to apply to be lead plaintiff.
Levi & Korsinsky Reminds Zoetis Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 27, 2026 - ZTS Notice to Pension Funds, Asset Managers, and Fiduciaries: Zoetis' Companion Animal Segment Collapse Allegedly Cost Institutional Portfolios Hundreds of Millions
Levi & Korsinsky, LLP is reminding investors of Zoetis Inc. (NYSE: ZTS) about a pending securities class action lawsuit, with a lead plaintiff deadline of July 27, 2026. The lawsuit alleges that Zoetis concealed competitive and safety deterioration in its Companion Animal segment, leading to significant stock declines and losses for investors. Institutional investors are encouraged to evaluate their eligibility for lead plaintiff opportunities to recover alleged losses.
Levi & Korsinsky Reminds Zoetis Inc. Investors of the
Levi & Korsinsky, LLP is reminding investors of Zoetis Inc. (NYSE: ZTS) about an ongoing securities class action lawsuit, with a lead plaintiff deadline of July 27, 2026. The lawsuit alleges that Zoetis misrepresented the performance of its Companion Animal segment, leading to substantial losses for institutional investors when corrective disclosures revealed competitive and safety issues between August 2025 and May 2026. The firm encourages affected institutional investors to evaluate lead plaintiff opportunities to oversee the litigation and potentially recover losses.
Deadline Alert: Zoetis Inc. (ZTS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP is urging Zoetis Inc. (ZTS) shareholders who suffered losses to consider joining a class action lawsuit. The lawsuit alleges that Zoetis made misleading statements and failed to disclose critical information regarding weakening demand for its Companion Animal products, increased competition, and declining sales of key medications, which led to significant stock price drops. Investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, have until July 27, 2026, to file a lead plaintiff motion.
Deadline Alert: Zoetis Inc. (ZTS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP reminds investors of the July 27, 2026 deadline to file as lead plaintiff in a class action lawsuit against Zoetis Inc. (NYSE: ZTS). The lawsuit alleges that Zoetis made misleading statements and failed to disclose issues regarding weakening demand for its products, increased competition, and negative impacts on sales, leading to significant stock price drops. Investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, and suffered losses are encouraged to contact the firm.
Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Zoetis Inc. (NYSE: ZTS) and its officers, alleging violations of federal securities laws. The lawsuit claims that Zoetis made misleading statements about the growth and market share of its Companion Animal segment products, specifically Librela, Simparica Trio, Apoquel, and Cytopoint, failing to disclose weakening adoption and market share losses. Investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, are encouraged to join the class action, with a lead plaintiff deadline of July 27, 2026.
Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Zoetis Inc. (NYSE: ZTS), alleging that the company made false and misleading statements regarding its Companion Animal segment products between January 14, 2025, and May 6, 2026. The lawsuit claims that Zoetis failed to disclose weakening prescription growth for Librela, market share loss for Simparica Trio, and declining market share for its dermatology products Apoquel and Cytopoint. Investors who suffered losses are encouraged to join the lawsuit by July 27, 2026.
Levi & Korsinsky Reminds Zoetis Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 27, 2026 - ZTS
Levi & Korsinsky is reminding investors of Zoetis Inc. (NYSE: ZTS) about a pending class action lawsuit with a lead plaintiff deadline of July 27, 2026. The lawsuit alleges that Zoetis concealed competitive and safety issues within its Companion Animal segment, leading to significant stock drops after corrective disclosures. Institutional investors are encouraged to evaluate their options for recovery and consider lead plaintiff opportunities.
ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of a class action lawsuit against Zoetis Inc. (NYSE: ZTS) for alleged securities fraud. The lawsuit claims that Zoetis made false and misleading statements between January 14, 2025, and May 6, 2026, regarding issues with its Librela, Trio, Apoquel, and Cytopoint products, which led to investor losses. Investors who purchased the company's securities during this period are encouraged to contact the firm to discuss their rights.
Zoetis, Inc. Class A Trade Ideas — HAM:ZOE
This article compiles various trade ideas for Zoetis, Inc. Class A (HAM:ZOE), offering both long and short positions based on technical analysis. Traders discuss methodologies involving bullish/bearish pennants, Fibonacci retracement, GMMA analysis, and candlestick patterns. The ideas suggest potential entry points, stop-loss levels, and profit targets for the stock.
ZOETIS DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ZTS
Rosen Law Firm is encouraging investors of Zoetis Inc. (NYSE:ZTS) to secure legal counsel before the July 27, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Zoetis made false and misleading statements regarding the performance of its flagship Companion Animal products, including Librela, Simparica Trio, Apoquel, and Cytopoint, resulting in investor damages. Investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, may be entitled to compensation.
IDEXX Laboratories opens the week with a clear consensus, NASDAQ-100 shares in a steady trend
IDEXX Laboratories (IDXX) begins the week with a strong analyst consensus and a stable presence on the NASDAQ-100. Analysts largely maintain "Buy" or "Outperform" ratings, projecting mid-single-digit percentage upside and steady revenue growth, supported by the company's dominant position in companion-animal diagnostics and recurring revenue streams. The stock currently trades at a premium P/E multiple due to its robust business model and essential role in the veterinary diagnostics market.
Zoetis Inc. (NYSE: ZTS) Class Action Lawsuit Seeks Recovery
Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Zoetis Inc. (NYSE: ZTS) on behalf of investors who purchased securities between January 14, 2025, and May 6, 2026. The lawsuit alleges that Zoetis made misleading statements and failed to disclose issues regarding its key products, Librela, Simparica Trio, Apoquel, and Cytopoint, which led to a significant stock price drop. Investors have until July 27, 2026, to seek lead plaintiff status.
ZOETIS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ZTS
Rosen Law Firm is reminding investors of Zoetis Inc. (NYSE: ZTS) that the lead plaintiff deadline for a securities class action lawsuit is July 27, 2026. The lawsuit alleges that Zoetis made misleading statements regarding its animal health products, leading to investor losses when the true details of weakening sales and market share emerged. Investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, are encouraged to secure counsel.
Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP has announced a securities fraud class action lawsuit against Zoetis Inc. (ZTS) for investors who suffered losses. The lawsuit alleges that Zoetis misrepresented the performance of its key products, including Librela, Simparica Trio, Apoquel, and Cytopoint, failing to disclose weakening prescription growth, market share loss to competitors, and safety concerns. Shareholders who invested between January 14, 2025, and May 6, 2026, are encouraged to contact the firm before the July 27, 2026, lead plaintiff deadline.
Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
The Gross Law Firm has issued a notice to shareholders of Zoetis Inc. (NYSE: ZTS) to join a class action lawsuit. The suit alleges that the company made false and/or misleading statements regarding the performance of its key products, including Librela, Simparica Trio, Apoquel, and Cytopoint, leading to artificial inflation of its stock price. Shareholders who purchased ZTS shares between January 14, 2025, and May 6, 2026, are encouraged to contact the firm, with a lead plaintiff deadline of July 27, 2026.
Zoetis Deadline: ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit
The Rosen Law Firm reminds investors who purchased Zoetis Inc. (NYSE: ZTS) securities between January 14, 2025, and May 6, 2026, that they have until July 27, 2026, to move for lead plaintiff in a securities fraud lawsuit. The lawsuit alleges that Zoetis made false statements regarding its key Companion Animal products, including issues with Librela's veterinarian adoption, Simparica Trio's market share loss, and dermatology products' declining sales due to competition. Investors are encouraged to contact the law firm to learn more about joining the class action.
ZTS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Zoetis Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Zoetis Inc. (NYSE:ZTS) on behalf of investors who suffered losses between January 14, 2025, and May 6, 2026. The lawsuit alleges that Zoetis made misleading statements about its Companion Animal segment's growth, competitive standing, and market share, while failing to disclose issues with key products like Librela, Simparica Trio, Apoquel, and Cytopoint. Investors have until July 27, 2026, to request to be appointed as lead plaintiff.
Zoetis, Inc. Class A Actuals & Estimates (NYSE:ZTS)
This article provides an overview of Zoetis Inc. (NYSE: ZTS) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers frequently asked questions about the company's stock, such as earnings, revenue, dividends, market capitalization, and volatility, along with information on how to trade ZTS shares.
Zoetis Deadline: ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors who purchased Zoetis Inc. (NYSE: ZTS) securities between January 14, 2025, and May 6, 2026, of the July 27, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Zoetis made false statements and failed to disclose issues regarding declining sales and market share for its key Companion Animal products due to weakening veterinarian adoption of Librela and competition for Simparica Trio and its dermatology products. Investors are encouraged to contact the firm to learn more about joining the class action.
OP Asset Management Ltd Makes New Investment in Elanco Animal Health Incorporated $ELAN
OP Asset Management Ltd has made a new investment in Elanco Animal Health (ELAN), acquiring 341,444 shares valued at approximately $8.17 million. This investment positions Elanco with a "Moderate Buy" consensus rating among analysts and an average target price of $28.55. The company recently surpassed Q1 expectations with $0.40 EPS and $1.37 billion in revenue, further supported by recent insider share purchases.
Join Class Action to Recover Losses From Zoetis Inc. (ZTS) - Contact Levi & Korsinsky Before July 27, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Zoetis Inc. (NYSE:ZTS) on behalf of investors who suffered losses due to alleged securities fraud between January 14, 2025, and May 6, 2026. The lawsuit claims Zoetis made false statements and concealed issues regarding weakening veterinarian prescription growth for Librela, market share loss for Simparica Trio, and declining market share for dermatology products Apoquel and Cytopoint. Shareholders who purchased Zoetis stock during this period are encouraged to contact the firm to learn about their rights.
ZOE Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Zoetis, Inc. Class A (ZOE) stock through 2027, based on analyst ratings and estimates. It details the current stock price, historical performance, future earnings and revenue predictions, market capitalization, and dividend information. The report also addresses frequently asked questions about ZOE stock.
ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against Zoetis Inc. (NYSE: ZTS) for alleged securities fraud, encouraging investors who suffered losses between January 14, 2025, and May 6, 2026, to join. The lawsuit claims Zoetis made false and misleading statements, as its Librela medication faced weakening prescription growth due to FDA safety warnings, and its Trio, Apoquel, and Cytopoint products lost market share to competitors. Investors are urged to contact the firm before July 27, 2026.
Zoetis, Inc. Class A Actuals & Estimates (BX:ZOE)
This article provides an overview of Zoetis, Inc. Class A (ZOE) stock performance, financial actuals, and analyst estimates. It includes current stock price, historical highs and lows, market capitalization, upcoming earnings dates, and past financial results like revenue and net income. The article also touches on dividends, employee count, EBITDA, and analyst recommendations for potential investors.
Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Zoetis Inc. (NYSE: ZTS), alleging the company made false and misleading statements regarding its Companion Animal segment products. The lawsuit claims Zoetis failed to disclose weakening prescription growth for Librela, market share loss for Simparica Trio, and substantial market share loss for its dermatology products Apoquel and Cytopoint. Investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, are encouraged to join the case, with a lead plaintiff deadline of July 27, 2026.
ZOETIS DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS
The Rosen Law Firm is encouraging investors of Zoetis Inc. (NYSE: ZTS) who purchased securities between January 14, 2025, and May 6, 2026, to secure legal counsel before the lead plaintiff deadline of July 27, 2026. A class action lawsuit has been filed, alleging that Zoetis made false and misleading statements regarding its products' market performance and failed to disclose issues like weakening veterinarian adoption and market share loss to competitors. Investors are urged to contact The Rosen Law Firm for information on joining the class action.
Zoetis, Inc. Class A Actuals & Estimates (FWB:ZOE)
This article provides an overview of Zoetis, Inc. Class A (FWB: ZOE) stock, including its current price, historical performance, and analyst forecasts. It also details financial actuals and estimates such as earnings, revenue, dividends, market capitalization, and EBITDA, along with information on how to trade the stock.
